site:www.novartis.com - Search Images

525×280
www.novartis.com
Novartis Kisqali® (ribociclib) receives MHRA authorisation for the adjuvant treatment of HR+ ...
525×280
www.novartis.com
Novartis Kisqali® (ribociclib) receives MHRA authorisation for the adjuvant treatment of HR+ ...
525×280
www.novartis.com
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL ...

525×280
www.novartis.com
Entresto® (sacubitril and valsartan) | Novartis United States of America
525×280
www.novartis.com
Novartis continues strong momentum of sales growth with margin expansion, reaches key inno…
525×280
www.novartis.com
Novartis in Slovenia | Novartis

525×280
www.novartis.com
Novartis in Slovenia | Novartis
1835×1089
www.novartis.com
Our commitment to ethical and responsible use of Artificial Intellig…
660×370
www.novartis.com
Novartis Annual Report 2024 | Novartis
660×370
www.novartis.com
Novartis Annual Report 2024 | Novartis

570×380
www.novartis.com
Novartis 2023 Financial Results | Novartis
570×380
www.novartis.com
Novartis 2023 Financial Results | Novartis
660×370
www.novartis.com
Novartis 2024 Financial Results | Novartis
525×280
www.novartis.com
Contact | Novartis Australia

Some results have been hidden because they may be inaccessible to you.Show inaccessible results